

## **Rosetta Genomics to Present at 2015 Aegis Growth Conference**

**PRINCETON, N.J. and REHOVOT, Israel (October 1, 2015)** – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that Company management will participate in the upcoming 2015 Aegis Growth Conference being held from October 7-9, 2015 at the Encore at Wynn Las Vegas. Kenneth A. Berlin, Rosetta's President and Chief Executive Officer, will present a corporate overview and update on October 8, 2015 at 11:25 a.m. Pacific Time.

A live audio webcast of Mr. Berlin's presentation will be available in the investor section of Rosetta Genomics' website, <http://www.rosettagenomics.com>, where it will also be archived for 90 days

### **About Rosetta Genomics**

Rosetta develops and commercializes a broad range of microRNA-based and other high-value molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company also offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta's cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit [www.rosettagenomics.com](http://www.rosettagenomics.com).

### **Forward-Looking Statement Disclaimer**

Various statements in this release concerning Rosetta's future expectations, plans and prospects including, but not limited to statements relating to Rosetta Genomics having a best-in-class FISH testing program, Rosetta Genomics' testing turnaround times, Rosetta Genomics enhancing oncologist's treatment options and Rosetta Genomics achieving New York State approval for any or all of its tests, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

**Company Contacts:**

Rosetta Genomics

Ken Berlin, President & CEO

(609) 419-9003

[investors@rosettagenomics.com](mailto:investors@rosettagenomics.com)

**Investor Contacts:**

LHA

Anne Marie Fields

(212) 838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss

(310) 691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

###